What is the recommended treatment for individuals with hereditary elevated tryptase (HET)?

Hereditary Elevated Tryptase (Hereditary Alpha-Tryptasemia)

Primary Management Strategy

For individuals with hereditary alpha-tryptasemia (HαT), treatment focuses on symptom control with H1 and H2 antihistamines as first-line therapy, mast cell stabilizers for gastrointestinal and neuropsychiatric symptoms, and mandatory carriage of two epinephrine auto-injectors due to increased risk of severe anaphylaxis. 1, 2

Diagnostic Confirmation

Before initiating treatment, confirm the diagnosis through:

• Baseline serum tryptase measurement when asymptomatic (typically >8 ng/mL in HαT, though can be normal range) 1, 3
• TPSAB1 gene copy number testing via droplet digital PCR to identify alpha-tryptase gene duplications or triplications 3, 4
• Exclude systemic mastocytosis if baseline tryptase >20 ng/mL through bone marrow biopsy with KIT D816V mutation testing 5, 1

This diagnostic approach is critical because HαT prevalence is 12-21% in systemic mastocytosis patients, and distinguishing between these conditions avoids unnecessary bone marrow examinations in confirmed HαT cases. 3, 6

Symptom-Directed Pharmacotherapy

First-Line Daily Prophylaxis

• Combined H1 and H2 antihistamines for baseline symptom control (superior to either agent alone) 2, 3
  • H1 blockers address flushing (47% of patients), pruritus (69%), and urticaria (37%) 7
  • H2 blockers provide additional benefit for gastrointestinal symptoms including irritable bowel (30-60%), nausea (51%), and reflux (49-77%) 7

Additional Symptom-Specific Agents

• Leukotriene antagonists for respiratory and atopic manifestations 3, 4
• Cromolyn sodium (cromoglicic acid) for gastrointestinal symptoms (30-60% prevalence) and neuropsychiatric manifestations including exhaustion (85%), depressive episodes (59%), and memory impairment (59-68%) 3, 7
• Omalizumab (anti-IgE monoclonal antibody) is especially successful for urticaria and anaphylaxis in HαT patients who fail conventional therapy 3

Emergency Preparedness (Non-Negotiable)

All HαT patients must carry two epinephrine auto-injectors at all times due to 14-28% prevalence of anaphylaxis and increased severity risk. 1, 2, 7

Dosing by Age:

• >12 years: 500 μg (0.5 mg) IM 2
• 6-12 years: 300 μg (0.3 mg) IM 2
• <6 years: 150 μg (0.15 mg) IM 2

Acute Anaphylaxis Management:

• Immediate IM epinephrine into anterolateral thigh (no absolute contraindications) 2, 8
• Multiple doses may be required for severe hypotension or bronchospasm 2
• Aggressive IV fluid resuscitation with normal saline or lactated Ringer's at 5-10 mL/kg boluses 2, 8
• Measure serum tryptase at 1-2 hours post-symptom onset to document acute elevation 1, 2

Trigger Avoidance Strategy

Counsel patients to avoid specific triggers that precipitate mast cell degranulation:

• Extreme heat and hot water 1, 2
• Alcohol consumption 9, 2
• Physical stimuli including pressure, friction, and vibration 9
• Exercise postprandially if food-associated exercise-induced anaphylaxis suspected 1
• Stress, hormonal fluctuations, and infections 9, 2

Critical Medication Review

Review and potentially discontinue beta-blockers and ACE inhibitors as these medications increase anaphylaxis risk and severity in HαT patients. 1, 2 Coordinate with cardiology before making changes in patients with cardiovascular disease.

Safety Measures

• Medic Alert identification is mandatory because syncope can occur during episodes 1
• Patient and family education on proper epinephrine auto-injector technique 2
• Referral to specialized Allergy/Immunology center for comprehensive evaluation and long-term management 1

Monitoring Protocol

• Serial tryptase levels every 3-6 months once diagnosis established 1
• Complete allergologic workup including skin tests or specific IgE antibodies to identify concurrent IgE-mediated hypersensitivity 1
• Screen first-degree relatives with anaphylactic reactions or mast cell mediator release symptoms for HαT after measuring baseline tryptase 3

Important Clinical Pitfalls

Do not assume HαT is benign or asymptomatic. While approximately two-thirds of HαT carriers appear asymptomatic, the condition is a significant risk factor for severe anaphylaxis, particularly with insect venom or unknown triggers. 3, 4, 6 HαT shows a gene-dose effect where higher TPSAB1 copy numbers correlate with elevated basal tryptase and more severe symptoms. 7, 10

Do not confuse HαT with mast cell activation syndrome (MCAS). HαT patients can develop MCAS, but many do not. 9 MCAS requires episodic symptoms affecting at least 2 organ systems concurrently with documented acute mediator elevation on 2 or more occasions, whereas HαT is defined by persistently elevated baseline tryptase from genetic alpha-tryptase overproduction. 9

Recognize that concomitant conditions are common. HαT frequently coexists with Ehlers-Danlos syndrome (joint hypermobility in 28%), postural orthostatic tachycardia syndrome (POTS), and autonomic dysfunction, though these are not caused by mast cell activation. 9, 7